Drugs Made In America Acquisition Corp Rights
DMAAR
19 hedge funds and large institutions have $2.53M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$267K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$253K |
| 3 |
HCI
Harraden Circle Investments
New York
|
+$211K |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$183K |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$126K |
Top Sellers
DMAAR Hedge Fund Activity: Q1 2025 in Review
19 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q1 2025, worth a combined $2.53M.
Buyers outnumbered sellers: 19 funds opened new DMAAR positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $267K.
- 19 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $2.53M of Drugs Made In America Acquisition Corp Rights stock for Q1 2025.
- 19 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q1 2025 and 0 closed out, a net change of +19 holders.
- The largest Drugs Made In America Acquisition Corp Rights buyer in Q1 2025 was Polar Asset Management Partners, an estimated $267K added.
Based on aggregated 13F filings for Q1 2025.